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Comparison of Therapeutic Triiodothyronine Versus
Metoprolol in the Treatment of Myocardial Infarction in Rats
Kuo Zhang,1,2 Yi-Da Tang,1 Youhua Zhang,2 Kaie Ojamaa,2 Ying Li,2 Amandeep Singh Saini,2
Maria Alicia Carrillo-Sepulveda,2 Viswanathan Rajagopalan,3 and A. Martin Gerdes2
Background: Beta blockers are standard therapy for myocardial infarction (MI). Preclinical studies have shown
efficacy and safety of thyroid hormone (TH) treatment of cardiovascular disorders. Since THs interact with the
sympathoadrenergic system, this study aimed to compare triiodothyronine (T3) and metoprolol (Met) in the
treatment of rats with MI on pathophysiology and TH-adrenergic signaling.
Methods: Female Sprague–Dawley rats aged 12 weeks underwent left anterior descending coronary artery
ligation (MI) or sham surgeries. T3 (5lg/kg/day) or Met (100mg/kg/day) was given in drinking water imme-
diately after surgery for eight weeks. At the terminal of the experiments, the rats were subjected to morphological,
functional, and molecular examination.
Results: T3 and Met significantly enhanced left ventricular contractility (left ventricular fractional shortening
21.37– 2.58% and 21.14– 3.71%, respectively) compared to untreated MI (17.88– 1.23%), and decreased the
incidence of inducible atrial tachyarrhythmia by 87.5% and 62.5%, respectively. Although both treatments showed
efficacy, T3 but not Met showed statistically significant improvements compared to MI in arrhythmia duration, left
atrial diameter (T3 vs. MI 4.33– 0.63 vs. 5.65– 1.32mm; p< 0.05), fibrosis (6.1– 0.6%, 6.6– 0.6% vs. 8.2– 0.7%,
T3, Met vs. MI, respectively), and aortic vasorelaxation responsiveness to acetylcholine (pD2 6.97– 0.22, 6.83–
0.21 vs. 6.66– 0.22, T3, Met vs. MI, respectively). Quantitative polymerase chain reaction showed that T3 and Met
attenuated expression of genes associated with inflammation and oxidative stress and restored expression of ion
channels and contractile proteins.
Conclusion: These results support comparable efficacy of T3 andMet treatments, suggesting that T3 may provide a
therapeutic alternative to standardb-receptor blockade, especially for patients intolerant to treatmentwithb-blockers
after MI.
Keywords: triiodothyronine, metoprolol, myocardial infarction, heart function
Introduction
Cardiovascular diseases are a leading cause of mor-bidity and mortality worldwide (1). Thyroid hormones
(THs) are essential to maintain homeostasis of the heart and
vascular system (2). Even subtle changes in TH levels may
adversely impact the cardiovascular system, as evidenced by
clinical studies showing that subclinical hypothyroidism and
hyperthyroidism and low triiodothyronine (T3) syndrome are
associated with poor outcomes in patients with heart diseases
(3–7). Low TH function is frequently observed in clinical and
experimental studies and is increasingly recognized as a strong,
independent risk factor of poor prognosis (8,9), although it may
be difficult to determine if the altered TH condition is a cause or
consequence of the underlying cardiovascular disease. In ad-
dition, independent of serum TH concentrations, reduced car-
diac TH receptors (TR alpha and beta) expression and low
cardiac T3 levels are frequently observed in severe heart dis-
eases, including acute myocardial infarction (MI) and heart
failure (HF), indicating impairment in TH signaling in failing
hearts (9–11). Moreover, evidence is accumulating that TH
administration post MI and HF improves cardiac contractility
and myocardial remodeling, and improves cardiovascular risk
factors, especially lipid profiles (12,13). It was recently dem-
onstrated that T3 safely improved heart function and remodel-
ing in experimental models of MI and ischemia–reperfusion
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injury (14,15). However, it has not been shown whether such
a T3 treatment-monitoring protocol can serve as an efficient
therapeutic strategy in comparison with existing standard
therapies.
The myocardial b-adrenergic signaling pathway plays a
key role in the pathogenesis and progression of HF. In early-
stage HF, compensatory changes, including activation of the
sympathetic nervous system, occur in the cardiovascular
system to preserve cardiac output (16,17). Under conditions
of increased catecholamine stimulation, b-adrenergic recep-
tors (bARs) are desensitized to prevent overstimulation,
which ultimately contributes to attenuated bAR function and
decreased cardiac contractility. Cardiac bAR downregulation
and desensitization are largely responsible for chronic post-
MI decompensation and remodeling. Accordingly, restoration
of adrenergic signaling pathway with b-blockers or alterna-
tives preventing further bAR downregulation remains crucial
to improving survival and remodeling. It is well established
that chronic treatment with b-blockers improves LV contrac-
tility and cardiac remodeling and reverses receptor down-
regulation in failing hearts (18,19). Furthermore, reversal of
ventricular remodeling is also associated with favorable
changes in expression of key myocardial genes, such as b-
myosin heavy chain (MYH7), a-myosin heavy chain (MYH6),
and sarco/endoplasmic reticulum calcium-ATPase 2 (SER-
CA2), all TH-responsive genes (20). The favorable alterations
by b-blockers in fetal gene reprogramming of failing hearts
resemble the pattern produced by TH administration. A recent
study also suggested that gene expression of the stimulatory
alpha subunit G-protein, which is activated by the b1AR, may
be upregulated toward normal values by low-dose oral T3
therapy following MI in the heart (14). Other previous studies
mainly focused on synergistic interactions of both systems on
thermogenesis and metabolism, while relationships between
b-adrenergic and TH pathways in MI and HF remain poorly
understood (21). It was hypothesized that there may be cross-
talk between b-adrenergic and thyroid signaling pathways on
preserving heart function in a rat model of MI.
This study focused on a direct comparison between thera-
peutic physiologic doses of T3 andmetoprolol (Met), a standard
b1-blocker, on pathophysiology and TH-adrenergic signaling in
a rat model of MI. This is the first report to show that T3 is
comparable to Met in improving left ventricular (LV) function
and attenuating atrial tachyarrhythmia (ATA) susceptibility,
which was accompanied by alterations in expression of genes
involved in TH and adrenergic signaling, inflammation, oxi-
dative stress, ion channels, and contractile proteins.
Materials and Methods
Animals and study design
Adult female Sprague–Dawley rats aged 12 weeks (200–
224 g; Envigo, Indianapolis, IN) were subjected to left
anterior descending (LAD) coronary artery ligation, as pre-
viously published (14). The sham surgery group (n = 8) was
similarly treated, except the LAD artery was not occluded.
Immediately following MI surgery, survivors were randomly
assigned to the following groups: MI + vehicle (Veh; n = 11),
MI + T3 (n = 11), and MI +Met (n = 11). T3 was dissolved in
ethanol/glycerol and provided in drinking water at a dose of
5 lg/kg/day for eight weeks based on a method previously
described (14). Met was provided in drinking water at a dose
of 100mg/kg/day based on previously published studies (18).
The efficacy of the selected dose and delivery method was
confirmed by preliminary experiments in our laboratory.
Sham and MI + Veh rats received ethanol/glycerol formu-
lation in drinking water equivalent to that in the treatment
groups. The rats were housed up to three per cage in constant
humidity and temperature, and kept on a 12 h light/dark cycle
with food and water available ad libitum. All protocols were
approved by the Institutional Animal Care and Use Com-
mittee at New York Institute of Technology College of Os-
teopathic Medicine and were performed in accordance with
the Guide for the Care and Use of Laboratory Animals.
Echocardiographic measurements
At the end of the eight-week treatment period, echocar-
diography was performed using a GE Vivid 7 Dimension
System (GE Vingmed Ultrasound, Horten, Norway) coupled
with a M12L linear (Matrix) array ultrasound transducer
probe (5–13MHz). The rats were anesthetized with iso-
flurane (1.5%), and a parasternal short-axis view was ob-
tained in B-mode and recorded in M-mode, as previously
described (22). Myocardial wall movement was traced over
three to five cardiac cycles in the M-mode echocardiogram to
determine LV wall thickness and dimensions in systole and
diastole. The following parameters were measured: LV
fractional shortening (LVFS), anterior and posterior wall
thickness in end-diastole and -systole, and LV diastolic and
systolic internal diameters. Left atrial diameter was deter-
mined at the aortic valve level in long axis view.
Cardiac hemodynamic measurements
After echocardiography measurements, right carotid artery
catheterization was performed using a Scisense pressure-
volume catheter (Transonic Scisense, London, Canada) on rats
under isoflurane anesthesia, and data were recorded over 15–
20 minutes with maintenance of 1.5% isoflurane in oxygen.
The following data were recorded: heart rate (HR), LV systolic
pressure (LVSP), LV end-diastolic pressure (LVEDP), posi-
tive change in LV pressure over time (LV +dp/dt), negative
change in LV pressure over time (LV -dp/dt), and Tau.
Electrophysiology study and ATA inducibility test
After hemodynamic measurements were recorded, elec-
trophysiology tests were performed, as previously described
(22). Briefly, a 1.6F octopolar Millar electrophysiology
catheter (EPR-802; Millar Instruments, Inc., Houston, TX)
was inserted through the right jugular vein and advanced into
the right atrium. The catheter carries eight poles with three
pairs of electrodes to record atrial electrocardiograms (ECG)
and one pair for pacing. Standard surface ECG lead II and
three right atrial ECG were recorded using a PowerLab data
acquisition system (ADInstruments, Colorado Springs, CO).
Regular pacing and standard S1S2 pacing protocols were
consistently used to determine the sinus node recovery time
and atrial effective refractory period. Burst pacing containing
200 impulses at 50Hz was used to induce ATA. Each rat
received burst pacing 10 times, and the duration of subse-
quent spontaneous ATA was recorded. ATA was defined as
irregular rapid atrial arrhythmia with varying electrographic
morphology lasting ‡0.5 seconds, as previously reported
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(22). The arrhythmia duration in each animal was based on
average of 10 burst pacings.
Serum TH measurements
Following functional measurements on the closed chest an-
imals, a left thoracotomy exposed the heart and blood was
collected from the right ventricle and left to clot at room tem-
perature for 30 minutes and then centrifuged at 600 g for 15
minutes at 4C. The serum was immediately aliquoted and
stored at -80C until assayed for free T3 (fT3), total T3 (TT3),
free thyroxine (fT4), total T4 (TT4), and thyrotropin (TSH)
using enzyme-linked immunosorbent assay (ELISA) kits (TSH:
ALPCO,Salem,NH; fT3,TT3, fT4,TT4:Monobind, Inc., Lake
Forest, CA) according to the manufacturers’ instructions.
Tissue collection and Masson’s trichrome staining
After the heart was isolated, the aorta was clamped, and
0.2M of KCl was injected slowly into the LV through the
apex. Hearts were then immersed in ice-cold phosphate-
buffered saline, trimmed of vessels and adipose tissue, and
the weights of the heart and LV were recorded. Basal and
apical sections were stored at -80C and used for real time
quantitative polymerase chain reaction (qPCR) analysis. A
transverse mid-section of LV was preserved in 10% formalin
for subsequent sectioning and staining with Masson’s Tri-
chrome stain. Images were acquired using an Olympus DP72
microscope. Infarct area and infarct length were determined
histologically from a transverse slice at approximately the
midpoint of the base-apex axis (e.g., middle of the infarct).
Infarct area is the traced area of the infarct from this slice.
This provided a consistent estimation of infarct size while
also providing tissues for biochemical analyses from adjacent
apical and basal transverse slices. Transmural infarct tissue
area and fibrosis content were quantified using ImageJ and
Image-Pro plus software (Media Cyberetics, Bethesda, MD).
Vascular reactivity
Thoracic aortas were isolated and cleaned of perivascular
adipose and connective tissue in oxygenated Krebs solution
(130mM of NaCl, 14.9mM of NaHCO3, 4.7mM of KCl,
1.18mM of KH2PO4, 1.17mM ofMgSO4-7H2O, 1.56mM of
CaCl2-2H2O, 0.026mM of EDTA, 5.5mM of glucose; pH
7.4), and cut into segments 2mm in length. The aortic rings
were mounted on a wire myograph (Model 620M; DMT,
Copenhagen, Denmark) and placed in a myograph chamber
filled with 5mL of Krebs buffer, maintained at 37C, and
continuously aerated with 95%O2-5%CO2. Changes in force
generation were documented using a PowerLab 8/35 data
acquisition system (ADInstruments, Colorado Springs, CO).
In all experiments, integrity of aortas was assessed by stim-
ulation with 120mM of KCl. To test for the presence of
endothelium, segments were contracted with 1 lM of phen-
ylephrine (PE) from Fluka (Sigma–Aldrich, St. Louis, MO).
Once the vessels reached a stable maximum tension, the
vessels were stimulated with 10 lM of ACh from Sigma–
Aldrich, and relaxation was confirmed (>80%). After a 20-
minute washout period, the aortic rings were precontracted
with 1lM of PE until a stable contraction was reached, fol-
lowed by a cumulative concentration–response curve of ACh
from 1 nM to 10 lM.
Real-time qPCR for gene expression
Total RNA was isolated from left ventricles using TRIzol
reagent followed by a RNA purification kit (cat. no.
12183018A; Thermo Fisher Scientific, Pittsburgh, PA) and
DNase kit (Qiagen, Valencia, CA). RNA concentration was
measured using Nanodrop 1000 (Thermo Fisher Scientific).
RNA (1lg) was reverse transcribed to cDNA using a RT2
First Strand Kit (Qiagen), and then amplified by PCR using a
96-well custom-designed primer plate for more than 90 genes
using a SYBR Green Kit (Qiagen) and ABI StepOnePlus.
mRNAs were normalized to the expression of housekeeping
genes, Ppia (cyclophilin A) and Rplp1 (ribosomal protein,
large, P1). Data analysis used the DDCt method according to
the SABioscience expression analysis online software (Qia-
gen). Results for each gene are expressed as 2–DDCt values
relative to the mean value of the sham group. Analysis used
RNA isolated from six animals per group.
Statistical analysis
Continuous data are expressed as means– standard devia-
tion and were compared using one-way analysis of variance
with Bonferroni correction for multiple comparisons. The in-
cidence of ATA was compared using Fisher’s exact test. The
ATA duration data are expressed as medians (Q1, Q3) and
were compared using a nonparametric Kruskal–Wallis test
followed by Dunn’s multiple comparison test. The myograph
aortic vessel relaxation responses are expressed as a percent-
age relative to maximal contractile response to 1lM of PE.
The maximal effect elicited by ACh (Emax) and the sensitivity
to ACh (pD2) were measured to assess aortic relaxation re-
sponsiveness toACh. GraphPad Prism v7.0 statistical software
(GraphPad Software, Inc., SanDiego, CA)was used to analyze
the data. Significance was accepted at p< 0.05.
Results
Morphometric changes
As presented in Table 1, body weights were similar among
the four groups. In MI +Veh, MI + T3, and MI +Met groups,
heart weight, LV weight, and their ratios with respect to body
weight were significantly increased compared to the sham
group, indicating hypertrophy after MI.
Serum TH levels
Serum THs are shown in Figure 1. Following T3 treatment,
serum fT3 and TT3 levels (Fig. 1A and B) were not signifi-
cantly increased above normal. It has been shown in multiple
animal models of HF that the administered dose of T3 pre-
serves cardiac tissue T3 levels while maintaining serum THs
within the reference range (9,23,24). As expected, fT4, TT4,
and TSH levels (Fig. 1C–E) were slightly yet significantly
decreased inMI+T3 rats, indicating amild feedback inhibition
response to the hypothalamic–pituitary–thyroid axis. These
data confirmed a physiological effect of the treatment with T3.
T3 and Met improved LV morphological
and functional changes
There was a significant decrease in LVFS and anterior wall
thickness and an increase in LV dimension after MI. T3 and
Met treatments both markedly increased LVFS, without
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affecting LV dimension and wall thickness (Fig. 2A–H).
Following MI, LA diameter was significantly enlarged in MI
and was prevented by T3, although it was not significantly
different between MI + Veh and MI +Met groups (Fig. 2D).
HR was not significantly increased in T3-treated rats com-
pared to shams. However, a slight increase in the T3-treated
group coupled with a slight reduction in Met resulted in a
significant difference between the two treatment groups
(Fig. 3A). MI resulted in a significant reduction in LV +dp/dt
and -dp/dt, and an increase in LVEDP and Tau, without
affecting LV systolic pressure (Fig. 3B–F). T3 and Met treat-
ments significantly improved LV +dp/dt and tended to increase
LV -dp/dt compared to the MI + Veh group. LVEDP and Tau
were decreased by T3 but unaffected by Met treatment.
T3 and Met reduced ATA inducibility
There was no ATA induction in sham rats. ATA induc-
ibility was significantly increased in MI + Veh rats ( p < 0.05)
and was significantly attenuated by both T3 ( p < 0.05) and
Met ( p < 0.05; Fig. 4A). Following MI, induced ATA dura-
tion was also increased. The duration was significantly de-
creased with T3 treatment ( p < 0.05) but not affected by Met
treatment ( p = 0.1; Fig. 4B).
Changes in infarct parameters and left atrial fibrosis
Compared to MI + Veh hearts, histological analysis indi-
cated a significant reduction of 19% in the infarct area of T3-
treated MI hearts (Table 2). A comparable reduction was
noted in the Met treated MI hearts. The MI + T3 group was
associated with a significant reduction in infarct length and
increased viable tissue area within the infarct segment. As
shown in Table 2, T3 treatment significantly decreased left
atrial interstitial fibrosis by 25.2% compared with the vehicle-
treated MI groups.
T3 ameliorated MI-induced endothelial dysfunction
Aortas from MI + Veh rats had severe impairment in
endothelium-dependent relaxation in response to ACh com-
pared to sham,with a rightward shift of theACh dose–response
FIG. 1. Serum thyroid hormone levels. (A) free triiodothyronine (fT3); (B) total triiodothyronine (TT3); (C) free thy-
roxine (fT4); (D) total thyroxine (TT4); (E) thyrotropin (TSH). *p< 0.05 vs. sham, MI + Veh and MI + Met; n= 8 for sham
and n = 11 for the other three groups. MI, myocardial infarction; Veh, vehicle; Met, metoprolol.
Table 1. Morphometric Data
Sham MI + Veh MI + T3 MI + Met
BW (g) 266 – 22 288– 20 285– 20 270 – 13
HW (mg) 881 – 93 1191– 201* 1345– 173* 1228– 165*
LVW (mg) 609 – 67 771– 79* 848– 117* 755 – 80*
HW/BW (mg/g) 3.3 – 0.1 4.1 – 0.5* 4.7 – 0.4* 4.6 – 0.7*
LVW/BW (mg/g) 2.3 – 0.1 2.7 – 0.2* 3.0 – 0.3* 2.7 – 0.3*
Values are expressed as means – standard deviation.
*p<0.05 vs. sham; n=8 for sham and n=11 for the other three groups.
MI, myocardial infarction; Veh, vehicle; T3, triiodothyronine; Met, metoprolol; BW, body weight; HW, heart weight; LVW, left
ventricle weight.
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curve (Fig. 5A).Aortas from theMI+Veh group exhibited less
sensitivity to ACh (pD2: 6.66– 0.21) in comparison to aortas
from the sham group (pD2: 7.19– 0.16; p< 0.05; Fig. 5B).
Furthermore, the maximal effect of ACh (Emax) was signifi-
cantly lower in MI + Veh rats (79.5– 4.0%) in comparison to
the sham group (96.9– 1.9%; p< 0.05; Fig. 5C). This effect
was reversed by T3 (90.6– 3.5%) and Met treatment
(90.1– 6.5%) versus vehicle treatment (79.5– 4.0%; Fig. 5C).
Importantly, ACh-induced endothelium-dependent vasor-
elaxation was significantly potentiated by T3 (6.97– 0.22;
p< 0.05) but not by Met (6.83– 0.21; p> 0.05) treatment
compared to the MI + Veh rats. pD2 was normalized by T3
treatment, with no significant difference between MI + T3 and
sham groups.
T3 and Met attenuated inflammation and oxidative
stress, regulated cardiac genes, and altered genes
in thyroid–adrenergic signaling pathways
As shown in Figure 6A–H, the expression of thyroid hor-
mone receptor alpha (TRa) was significantly decreased in the
MI + Veh group, whereas T3 ( p= 0.08) and Met ( p= 0.33)
treatments had a tendency to increase its expression compared
to vehicle-treated rats. This trend in expression was similar for
thyroid hormone receptor beta (TRb), although statistical sig-
nificancewas not obtained. The primarymembrane transporter
of T3, monocarboxylic acid transporter 10 (MCT10), was de-
creased in MI and increased 1.85-fold with T3 treatment, al-
though this did not reach significance. b1AR was significantly
FIG. 4. Atrial tachyarrhythmias (ATA) inducibility. ATA incidence (A) and duration (B) in the studied groups are shown.
ATA duration data are presented as median (Q1, Q3). *p< 0.05 vs. sham; #p < 0.05 vs. MI + Veh; n = 8 for sham and n = 11
for the other three groups.
FIG. 3. Left ventricular hemodynamics. Values are presented as means– SD. (A) Heart rate (HR); (B) left ventricular
systolic pressure (LVSP); (C) left ventricular end-diastolic pressure (LVEDP); (D) positive change in pressure over time
(+dP/dt); (E) negative change in pressure over time (–dP/dt); (F) Tau. *p < 0.05 vs. sham; #p < 0.05 vs. MI + Veh; xp< 0.05
vs. MI + T3; n= 8 for sham and n= 11 for the other three groups.
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decreased in failing hearts and increased with T3 and Met
treatments. b2AR was downregulated following MI and upre-
gulated by both T3 and Met treatments, although this was not
statistically significant. In addition, adenylate cyclase 6
(Adcy6) and stimulatory G-protein a (Gnas) expression were
downregulated in MI + Veh rats. T3 and Met treatments
increased the expression of Adcy6 2.82-fold and 1.46-fold,
respectively, but these changes did not reach statistical sig-
nificance. T3 and Met treatments significantly increased ex-
pression ofGnas to levels comparable with sham rats. Cardiac
troponinT (Tnnt2)was significantly decreased inMI+Veh rats
compared to sham rats and was normalized by T3 and Met
treatments. Natriuretic peptide precursor B (Nppb) was in-
creased inMI+Veh and significantly decreased inMI+T3 and
MI + Met rats. SERCA2 and phospholamban (Pln) were
downregulated in failing hearts and upregulated to shamvalues
by T3 treatment. Met significantly increased Pln but had no
effect on SERCA2. The reduction of Myh6 following MI was
prevented byT3 treatment, as it was 2.25-fold higher thanMI+
Veh rats. The increase (1.33-fold) inMyh7 inMI+Veh ratswas
reduced 0.38-foldwithT3 treatment.Metwaswithout effect on
Myh6 orMyh7 expression.
T3 andMet significantly reduced the expression of collagen
type I (Col1a1; Fig. 7). Tissue inhibitor of metalloproteinase 2
(Timp2) was upregulated, and Collagen type III alpha 1
(Col3a1) was downregulated, although statistical significance
was not reached following T3 and Met treatments. The in-
creases in inflammatory markers, interleukin-6 (IL-6) and IL-
10, followingMI were completely abrogated and prevented by
T3 and Met treatments. Catalase was decreased in MI + Veh
and rescued by T3 and Met treatments. The reduction in
superoxide dismutase 2 (Sod2) was prevented by T3 treat-
ment ( p = 0.05). T3 restored the expression of nitric oxide
synthase 3 (Nos3) and increased vascular endothelial growth
factor A (Vegfa) levels 3.98-fold ( p = 0.08). Both T3 and
Met significantly increased voltage-gated potassium chan-
nel Kv4.2 (Kcnd2), which was depressed inMI +Veh hearts.
While T3 partially returned voltage-gated potassium chan-
nel Kv1.5 (Kcna5) expression to almost that of sham levels,
Met did not.
FIG. 5. Effect of T3 and Met administration in MI-induced impaired endothelium-dependent relaxation. (A) Cumulative
concentration–response curves to ACh for the sham, MI + Veh, MI + T3, and MI + Met groups. Values of pD2 (B) and
Emax (C) are shown. *p < 0.05 vs. sham; #p < 0.05 vs. MI + Veh; n= 8 for sham and n= 9 for the other three groups.
Table 2. Changes in Infarct Parameters and Left Atrial Fibrosis
Sham MI + Veh MI + T3 MI + Met
Infarct area (mm2) N/A 10.33 – 0.51 8.38– 0.69# 8.06 – 0.85#
Infarct length (mm) N/A 9.24 – 0.41 7.81– 0.46# 7.58 – 0.56#
Percent viable area within infarct zone (%) N/A 21.51 – 2.69 23.90– 3.94# 20.46 – 1.40
Left atrial fibrosis (%) 3.35 – 0.23 8.16 – 0.71 6.10– 0.55*,# 6.57 – 0.64*
Values are expressed as means – standard error of the mean.
*p < 0.05 vs. sham; #p < 0.05 vs. MI + Veh; n = 8 for sham and n = 11 for the other three groups.
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Discussion
Recent studies suggest a growing need to reexamine THs as
a potential therapy for cardiovascular disorders (9,13–
15,24,25). However, THs have not been experimentally tested
in comparison with existing standard therapies. This study
directly compared the effects of T3 replacement therapy with
Met, a commonly used b-blocker, onmyocardial and electrical
remodeling, LV function, vascular reactivity, and gene regu-
lation in a rat model of MI. The findings further extended past
observations by showing that: (i) treatment with a physiological
dose of T3 for eight weeks improved endothelial and heart
physiology, with arrhythmia inducibility duration, left atrial
diameter/fibrosis, and aortic vasorelaxation responsiveness be-
ing statistically different from untreated MI, whereas Met
treatment was not; (ii) these treatments were associated with
favorable alterations in genes regulating contractile function,
thyroid signaling, adrenergic signaling, inflammation, and oxi-
dative stress; and (iii) beneficial crosstalk between cardiac TH
and b-adrenergic signaling pathways after MI may be induced
by either therapy.
In the present study, a strategy was used to investigate
arrhythmias that was identical to that of a previous MI study
using a similar physiological T3 dosage regimen (14). The
only significant difference is that in this study, the number of
burst pacings per animal was doubled for all the groups,
which would increase precision and rigor of the experiment.
As expected, the current MI + T3 group showed a similar
improvement in attenuation of inducible ATA incidence, as
observed in the previous study (i.e., 85.2% vs. 87.9%).
However, Met offered a 62.5% improvement. Of note, Met
did not improve ATA duration significantly, while T3 did in
both cases. AF is considered to be the most common cardiac
arrhythmia and an independent risk factor for mortality (26).
FIG. 6. Expression of thyroid hormone signaling, adrenergic signaling, and cardiac genes. Gene expression was nor-
malized using cyclophilin A and Rlpl 1. (A) Thyroid hormone receptor a (Tra), thyroid hormone receptor b (TRb); (B)
monocarboxylate transporter (MCT); (C) adrenergic receptors (AR); (D) adenylate cyclase 6 (Adcy6); (E) G-protein
stimulatory a subunit (Gnas); (F) troponin T type 2 (Tnnt2); (G) natriuretic peptide precursor B (Nppb); (H) sarcoplasmic/
endoplasmic reticulum Ca2+ transporting 2 (SERCA2), phospholamban (Pln); myosin heavy chain a isoform (Myh6),
myosin heavy chain b isoform (Myh7). *p < 0.05 vs. sham; #p< 0.05 vs. MI + Veh; n = 6 per group.
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In long-term post-MI follow-up, AF can be observed in as
many as 39% of patients (27). However, the incidence of AF
in patients with heart disease related to borderline low THs is
not clear at present. These results suggest that physiological
doses of T3 in low TH conditions do not promote arrhyth-
mias, a finding confirmed recently by the TRUST trial (28).
Wandell et al. also showed that women diagnosed with AF
who were being treated with T4 had a decreased risk of
mortality (29). Previous studies reported that mutations in
Kcna5 could enhance AF susceptibility (30). T3 but not Met
restored expression of this gene, which may be related to
greater reduction in AF inducibility by T3. Taken together,
this study expands the possibility of T3 replacement therapy
as a potentially valuable approach to prevent or reduce ar-
rhythmias in HF and warrants well-designed clinical trials.
It was previously shown that chronic serum hypothyroid-
ism eventually leads to dilated HF involving myocyte
lengthening from series addition of sarcomeres, despite car-
diac atrophy from hemodynamic unloading (31). This unique
remodeling pattern of increased length:width ratio is specific
to dilated HF. Hypothyroidism, like all heart diseases leading
to HF, results in re-expression of the fetal gene program of
which many genes have been shown to be transcriptionally
regulated by T3, thus reflecting cardiac tissue hypothyroid-
ism in HF. Indeed, alterations in serum THs does not nec-
essarily suggest altered thyroid status in the heart (32). In the
FIG. 7. Expression of extracellular matrix pathway, inflammation, oxidative stress, and ion channel genes. Gene ex-
pression was normalized using cyclophilin A and Rlpl 1. (A) Matrix metallopeptidase 2 (Mmp2), tissue inhibitor of
metalloproteinase 2 (Timp2); (B) collagen type I alpha 1 (Col1a1), collagen type III, alpha 1 (Col3a1); (C) interleukin 6 (IL-
6), interleukin 10 (IL-10); (D) superoxide dismutase 2 (Sod2), catalase (Cat); (E) vascular endothelial growth factor A
(Vegfa); (F) nitric oxide synthase 3 (Nos3); (G) hyperpolarization activated cyclic nucleotide–gated channel (Hcn); (H)
potassium voltage-gated channel, Shal-related subfamily, member 2 (Kcnd2), potassium voltage-gated channel, shaker-
related subfamily, member 5 (Kcna5). *p< 0.05 vs. sham; #p < 0.05 vs. MI + Veh; n = 6 per group.
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current study and past related studies on myocardial ischemic
injury (14,15,33), T3 (the potent and active form of TH) was
not decreased in MI + Veh, although expression of deiodi-
nases, TRs, MCT transporters, midkine, and/or myosin heavy
chains were impaired. Experimental evidence revealed that
changes in cardiac tissue T3 concentrations in MI and HF
were a result of increased deiodinase 3 activity and reduced
deiodinase 1 and deiodinase 2 activity (34,35). Additionally,
downregulation of TRs also contributes to a lower level of T3
action in cardiac tissue, resulting in tissue hypothyroidism
(10,36,37). Furthermore, systemic TH treatment partially or
wholly restored these molecular and other physiological de-
fects. These repeated observations strongly indicate the im-
portance of localized TH signaling and availability in the
ischemic heart (13,25). A safe and efficacious TH treatment
strategy has now been repeatedly demonstrated in this and
other rat models of HF, offering optimism for pursuing similar
trials in human.
THs regulate b1AR density, with downregulation observed
in hypothyroidism and upregulation in hyperthyroidism (38).
This mechanism is believed to be largely responsible for
changes in HR observed in chronic hypothyroidism and hy-
perthyroidism. This study confirmed downregulation of b1/
b2 receptors in MI and restoration with T3 or Met treatment.
Downstream signaling mediators including Adcy6 and Gnas
were downregulated in MI, and T3 restored Gnas expression
(14). Similar to T3, Met led to partial or complete restoration
in TRa, bARs, Gnas, Pln, Nppb, Tnnt 2, Col1a1, IL-6, IL-10,
Catalase, and voltage-gated potassium channel Kv4.2 ex-
pression. These results suggest extensive crosstalk between
cardiac thyroid and cardiac adrenergic signaling systems,
which is in accordance with previous reports (39). Physiolo-
gical improvements significant for some parameters with T3,
but not Met, were likely mediated by reversal of fetal genes
(SERCA2, Myh6, and Myh7), which were not observed with
Met treatment. Human studies showing improvement in TH
signaling with b-blocker treatment of HF support the rele-
vancy of the current findings (20). While the present study
suggests that low TH function post MI or HF may underlie
downregulation of bARs, it is not feasible to investigate this in
humans, since b-blockers are standard therapy. However,
some patients do not tolerate b-blockers well. The findings
suggest that it may be worthwhile to explore the potential
therapeutic utility of THs in this patient population in addition
to restoration of depressed TH function in HF patients.
Endothelial dysfunction is frequently observed in the
evolution and progression of ischemic HF and is associated
with poor prognosis (40). This study found that endothelium-
dependent vasodilatation is severely impaired in MI + Veh
rats and was significantly improved by T3 and Met treat-
ments. Many mechanisms can contribute to the improvement
of endothelial function. Restoration of TRa following T3 and
Met treatments can increase coronary blood flow and de-
crease coronary artery resistance (41). Increased activation of
the b2AR signaling pathway by T3 was previously shown to
modulate vascular reactivity, which may also play a role, since
obvious upregulation of b2AR was observed from T3 and Met
therapies, though it did not reach significance due to some
values with high variation (42). Besides genomic signaling
effects, T3 also potentiates vasodilatory effects via the acti-
vation of PI3K/Akt signaling and nitric oxide synthase in en-
dothelial and vascular smooth muscle cells (43). Recently,
T3-induced rapid vascular relaxation via a PKG/VASP sig-
naling pathway was shown, highlighting non-genomic and
direct effect of T3 in the vasculature (44). In the present study,
Nos3 and Vegfa (to a lesser extent) were upregulated by T3
treatment. These changes contribute to the amelioration of
endothelial dysfunction in MI. Low-grade inflammation post-
MI might also contribute to endothelial dysfunction. In-
flammation was attenuated by T3 and Met treatments here, as
confirmed by a reduction in elevated IL-6 and IL-10mRNA in
MI hearts, thus leading to improved vascular reactivity (45).
As emphasized, serum TH levels may not reflect cardiac
tissue T3 content. Normalization of myocardial TH content
with TH replacement therapy in different cardiac disease
models has been clearly demonstrated (9,23,24). However, it
remains unknown whether Met can also affect cardiac tissue
T3 levels. Identification of a serum biomarker tracking with
cardiac tissue T3 levels would be a major diagnostic advance
in the field. Some variation was observed in serum T3 levels
with the method of administration of T3 in the drinking
water. However, a similar variation is typically observed with
other modes of treatment (46,47). The reasons the method of
administration of T3 in the drinking water was chose are that
the effective performance of T3 is repeatedly seen without
producing untoward side effects, the procedure is minimally
invasive, similar to human treatment, and can be readily
adjusted by changing the T3 concentration in water. Finally,
since the focus of the study was to assess the effect of T3
treatment on MI, and not investigation of hyperthyroidism, a
T3 + sham group was not included.
Conclusions
Short-term, therapeutic treatment of T3 in HF patients has
been well-tolerated and efficacious (48,49). However, long-
term studies are lacking. The findings from this animal study
support growing evidence that long-term T3 therapy in HF
patients may confer comparable benefits with those of current
standard therapy. These data suggest that improvements in b-
adrenergic signaling offered by b-blockade may also result
from TH treatment.
Acknowledgments
This work was supported by the National Heart, Lung, and
Blood Institute of the National Institutes of Health (Bethesda,
MD) under Award Number R01HL103671 (AG). The content
is solely the responsibility of the authors and does not neces-
sarily represent the official views of the National Institutes of
Health. We also acknowledged the National Natural Science
Foundation of China (No. 81470485), Capital Clinical Fea-
tured Application Research Project (No. z151100004015175),
and CAMS Innovation Fund for Medical Sciences (CIFMS
2016-I2M-1-009).
Author Disclosure Statement
The authors have nothing to disclose.
References
1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR,
Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C,
Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D,
Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey
808 ZHANG ET AL.
RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K,
Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR,
Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond
WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani
SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM,
Wong SS, Muntner P 2017 Heart disease and stroke sta-
tistics—2017 update: a report from the American Heart
Association. Circulation 135:e146–e603.
2. Klein I, Ojamaa K 2001 Thyroid hormone and the cardio-
vascular system. N Engl J Med 344:501–509.
3. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scar-
lattini M, L’Abbate A, Donato L 2003 Low-T3 syndrome: a
strong prognostic predictor of death in patients with heart
disease. Circulation 107:708–713.
4. Biondi B, Cooper DS 2008 The clinical significance of
subclinical thyroid dysfunction. Endocr Rev 29:76–131.
5. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller
LH, Burke GL, Tracy RP, Ladenson PW 2006 Thyroid
status, cardiovascular risk, and mortality in older adults.
JAMA 295:1033–1041.
6. Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman
PJ, Feddema P, Michelangeli V 2005 Subclinical thyroid
dysfunction as a risk factor for cardiovascular disease. Arch
Intern Med 165:2467–2472.
7. Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E,
Mariani F, L’Abbate A, Pingitore A 2007 Association be-
tween increased mortality and mild thyroid dysfunction in
cardiac patients. Arch Intern Med 167:1526–1532.
8. Wang W, Guan H, Gerdes AM, Iervasi G, Yang Y, Tang
YD 2015 Thyroid status, cardiac function, and mortality in
patients with idiopathic dilated cardiomyopathy. J Clin
Endocrinol Metab 100:3210–3218.
9. Weltman NY, Ojamaa K, Schlenker EH, Chen YF, Zucchi
R, Saba A, Colligiani D, Rajagopalan V, Pol CJ, Gerdes
AM 2014 Low-dose T(3) replacement restores depressed
cardiac T(3) levels, preserves coronary microvasculature
and attenuates cardiac dysfunction in experimental diabetes
mellitus. Mol Med 20:302–312.
10. Pantos C, Mourouzis I, Galanopoulos G, Gavra M, Peri-
menis P, Spanou D, Cokkinos DV 2010 Thyroid hormone
receptor alpha1 downregulation in postischemic heart fail-
ure progression: the potential role of tissue hypothyroidism.
Horm Metab Res 42:718–724.
11. Kinugawa K, Minobe WA, WoodWM, Ridgway EC, Baxter
JD, Ribeiro RC, Tawadrous MF, Lowes BA, Long CS, Bris-
tow MR 2001 Signaling pathways responsible for fetal gene
induction in the failing human heart: evidence for altered
thyroid hormone receptor gene expression. Circulation 103:
1089–1094.
12. Zhao M, Liu L, Wang F, Yuan Z, Zhang X, Xu C, Song Y,
Guan Q, Gao L, Shan Z, Zhang H, Zhao J 2016A worthy
finding: decrease in total cholesterol and low-density lipo-
protein cholesterol in treated mild subclinical hypothy-
roidism. Thyroid 26:1019–1029.
13. Gerdes AM, Ojamaa K 2016 Thyroid hormone and cardi-
oprotection. Compr Physiol 6:1199–1219.
14. Rajagopalan V, Zhang Y, Ojamaa K, Chen YF, Pingitore A,
Pol CJ, Saunders D, Balasubramanian K, Towner RA, Gerdes
AM 2016 Safe oral triiodo-L-thyronine therapy protects from
post-infarct cardiac dysfunction and arrhythmias without
cardiovascular adverse effects. PLoS One 11:e0151413.
15. Rajagopalan V, Zhang Y, Pol C, Costello C, Seitter S, Lehto
A, Savinova OV, Chen YF, Gerdes AM 2017 Modified low-
dose triiodo-L-thyronine therapy safely improves function
following myocardial ischemia–reperfusion injury. Front
Physiol 8:225.
16. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE,
Sundlof G, Mark AL 1986 Direct evidence from intraneural
recordings for increased central sympathetic outflow in
patients with heart failure. Circulation 73:913–919.
17. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J,
Louridas G, Butler J 2009 The sympathetic nervous system
in heart failure physiology, pathophysiology, and clinical
implications. J Am Coll Cardiol 54:1747–1762.
18. Rinaldi B, Donniacuo M, Sodano L, Gritti G, Martuscelli E,
Orlandi A, Rafaniello C, Rossi F, Calzetta L, Capuano A,
Matera MG 2015 Effects of chronic treatment with the new
ultra-long-acting beta2-adrenoceptor agonist indacaterol
alone or in combination with the beta1-adrenoceptor blocker
metoprolol on cardiac remodelling. Br J Pharmacol 172:
3627–3637.
19. Bristow MR 2011 Treatment of chronic heart failure with
beta-adrenergic receptor antagonists: a convergence of re-
ceptor pharmacology and clinical cardiology. Circ Res 109:
1176–1194.
20. Kao DP, Lowes BD, Gilbert EM, Minobe W, Epperson LE,
Meyer LK, Ferguson DA, Volkman AK, Zolty R, Borg CD,
Quaife RA, Bristow MR 2015 Therapeutic molecular
phenotype of beta-blocker-associated reverse-remodeling
in nonischemic dilated cardiomyopathy. Circ Cardiovasc
Genet 8:270–283.
21. Silva JE, Bianco SD 2008 Thyroid–adrenergic interactions:
physiological and clinical implications. Thyroid 18:157–
165.
22. Zhang Y, Dedkov EI, Lee B, 3rd, Li Y, Pun K, Gerdes AM
2014 Thyroid hormone replacement therapy attenuates at-
rial remodeling and reduces atrial fibrillation inducibility in
a rat myocardial infarction-heart failure model. J Card Fail
20:1012–1019.
23. WeltmanNY, Ojamaa K, Savinova OV, ChenYF, Schlenker
EH, Zucchi R, Saba A, Colligiani D, Pol CJ, Gerdes AM
2013 Restoration of cardiac tissue thyroid hormone status in
experimental hypothyroidism: a dose–response study in fe-
male rats. Endocrinology 154:2542–2552.
24. Weltman NY, Pol CJ, Zhang Y, Wang Y, Koder A, Raza S,
Zucchi R, Saba A, Colligiani D, Gerdes AM 2015 Long-term
physiological T3 supplementation in hypertensive heart dis-
ease in rats. Am J Physiol Heart Circ Physiol 309:H1059–
1065.
25. Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G,
Razvi S 2017 Thyroid hormones and cardiovascular dis-
ease. Nat Rev Cardiol 14:39–55.
26. Andersson T, Magnuson A, Bryngelsson IL, Frobert O,
Henriksson KM, Edvardsson N, Poci D 2013 All-cause
mortality in 272,186 patients hospitalized with incident
atrial fibrillation 1995–2008: a Swedish nationwide long-
term case-control study. Eur Heart J 34:1061–1067.
27. Jons C, Jacobsen UG, Joergensen RM, Olsen NT, Dixen U,
Johannessen A, Huikuri H, Messier M, McNitt S, Thomsen
PE 2011 The incidence and prognostic significance of new-
onset atrial fibrillation in patients with acute myocardial
infarction and left ventricular systolic dysfunction: a
CARISMA substudy. Heart Rhythm 8:342–348.
28. Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp
RGJ, Mooijaart SP, Sattar N, Aubert CE, Aujesky D, Bauer
DC, Baumgartner C, Blum MR, Browne JP, Byrne S,
Collet TH, Dekkers OM, den Elzen WPJ, Du Puy RS, Ellis
G, Feller M, Floriani C, Hendry K, Hurley C, Jukema JW,
T3 VS. METOPROLOL IN RATS WITH MYOCARDIAL INFARCTION 809
Kean S, Kelly M, Krebs D, Langhorne P, McCarthy G,
McCarthy V, McConnachie A, McDade M, Messow M,
O’Flynn A, O’Riordan D, Poortvliet RKE, Quinn TJ,
Russell A, Sinnott C, Smit JWA, Van Dorland HA, Walsh
KA, Walsh EK, Watt T, Wilson R, Gussekloo J 2017
Thyroid hormone therapy for older adults with subclinical
hypothyroidism. N Engl J Med 376:2534–2544.
29. Wandell P, Carlsson AC, Holzmann MJ, Arnlov J, Sund-
quist J, Sundquist K 2017 Comparison of mortality and
nonfatal cardiovascular events in adults with atrial fibril-
lation with versus without levothyroxine treatment. Am J
Cardiol 120:1974–1979.
30. Christophersen IE, Olesen MS, Liang B, Andersen MN,
Larsen AP, Nielsen JB, Haunso S, Olesen SP, Tveit A,
Svendsen JH, Schmitt N 2013 Genetic variation in
KCNA5: impact on the atrial-specific potassium current
IKur in patients with lone atrial fibrillation. Eur Heart J 34:
1517–1525.
31. TangYD,Kuzman JA, Said S, AndersonBE,WangX,Gerdes
AM 2005 Low thyroid function leads to cardiac atrophy with
chamber dilatation, impaired myocardial blood flow, loss of
arterioles, and severe systolic dysfunction. Circulation 112:
3122–3130.
32. Liu Y, Redetzke RA, Said S, Pottala JV, de Escobar GM,
Gerdes AM 2008 Serum thyroid hormone levels may not
accurately reflect thyroid tissue levels and cardiac function
in mild hypothyroidism. Am J Physiol Heart Circ Physiol
294:H2137–2143.
33. Chen YF, Pottala JV, Weltman NY, Ge X, Savinova OV,
Gerdes AM 2012 Regulation of gene expression with thyroid
hormone in rats with myocardial infarction. PLoS One 7:
e40161.
34. Wassner AJ, Jugo RH, Dorfman DM, Padera RF, Maynard
MA, Zavacki AM, Jay PY, Huang SA 2017 Myocardial
induction of type 3 deiodinase in dilated cardiomyopathy.
Thyroid 27:732–737.
35. Van den Berghe G 2014 Non-thyroidal illness in the ICU: a
syndrome with different faces. Thyroid 24:1456–1465.
36. Mourouzis I, Kostakou E, Galanopoulos G, Mantzouratou P,
Pantos C 2013 Inhibition of thyroid hormone receptor alpha1
impairs post-ischemic cardiac performance after myocardial
infarction in mice. Mol Cell Biochem 379:97–105.
37. Adamopoulos S, Gouziouta A,Mantzouratou P, Laoutaris ID,
Dritsas A, Cokkinos DV, Mourouzis I, Sfyrakis P, Iervasi G,
Pantos C 2013 Thyroid hormone signalling is altered in re-
sponse to physical training in patients with end-stage heart
failure and mechanical assist devices: potential physiological
consequences? Interact Cardiovasc Thorac Surg 17:664–668.
38. Bilezikian JP, Loeb JN 1983 The influence of hyperthy-
roidism and hypothyroidism on alpha- and beta-adrenergic
receptor systems and adrenergic responsiveness. Endocr
Rev 4:378–388.
39. Pantos C, Xinaris C, Mourouzis I, Perimenis P, Politi E,
Spanou D, Cokkinos DV 2008 Thyroid hormone receptor
alpha 1: a switch to cardiac cell ‘‘metamorphosis’’? J Physiol
Pharmacol 59:253–269.
40. Shantsila E, Wrigley BJ, Blann AD, Gill PS, Lip GY
2012A contemporary view on endothelial function in heart
failure. Eur J Heart Fail 14:873–881.
41. Suarez J, Wang H, Scott BT, Ling H, Makino A, Swanson E,
Brown JH, Suarez JA, Feinstein S, Diaz-Juarez J, Dillmann
WH 2014 In vivo selective expression of thyroid hormone
receptor alpha1 in endothelial cells attenuates myocardial
injury in experimental myocardial infarction in mice. Am J
Physiol Regul Integr Comp Physiol 307:R340–346.
42. Pappas M, Mourouzis K, Karageorgiou H, Tesseromatis C,
Mourouzis I, Kostopanagiotou G, Pantos C, Cokkinos DV
2009 Thyroid hormone modulates the responsiveness of rat
aorta to alpha1-adrenergic stimulation: an effect due to in-
creased activation of beta2-adrenergic signaling. Int Angiol
28:474–478.
43. Carrillo-Sepulveda MA, Ceravolo GS, Fortes ZB, Carvalho
MH, Tostes RC, Laurindo FR, Webb RC, Barreto-Chaves
ML 2010 Thyroid hormone stimulates NO production via
activation of the PI3K/Akt pathway in vascular myocytes.
Cardiovasc Res 85:560–570.
44. Samuel S, Zhang K, Tang YD, Gerdes AM, Carrillo-
Sepulveda MA 2017 Triiodothyronine potentiates vasor-
elaxation via PKG/VASP signaling in vascular smooth
muscle cells. Cell Physiol Biochem 41:1894–1904.
45. Turemen EE, Cetinarslan B, Sahin T, Canturk Z, Tarkun I
2011 Endothelial dysfunction and low grade chronic in-
flammation in subclinical hypothyroidism due to autoim-
mune thyroiditis. Endocr J 58:349–354.
46. Chen YF, Weltman NY, Li X, Youmans S, Krause D,
Gerdes AM 2013 Improvement of left ventricular re-
modeling after myocardial infarction with eight weeks L-
thyroxine treatment in rats. J Transl Med 11:40.
47. Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel
AM 2009 Physiological replacement of T3 improves left
ventricular function in an animal model of myocardial
infarction-induced congestive heart failure. Circ Heart Fail 2:
243–252.
48. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M,
Nucci D, L’Abbate A, Mariotti R, Iervasi G 2008 Acute ef-
fects of triiodothyronine (T3) replacement therapy in patients
with chronic heart failure and low-T3 syndrome: a random-
ized, placebo-controlled study. J Clin Endocrinol Metab 93:
1351–1358.
49. Hamilton MA, Stevenson LW, Fonarow GC, Steimle A,
Goldhaber JI, Child JS, Chopra IJ, Moriguchi JD, Hage A
1998 Safety and hemodynamic effects of intravenous tri-
iodothyronine in advanced congestive heart failure. Am J
Cardiol 81:443–447.
Address correspondence to:
A. Martin Gerdes, PhD
Department of Biomedical Sciences
New York Institute of Technology-College
of Osteopathic Medicine
Old Westbury, NY 11568
E-mail: agerdes@nyit.edu
Yi-Da Tang, MD, PhD
Department of Cardiology
State Key Laboratory of Cardiovascular Disease
Fuwai Hospital
National Center for Cardiovascular Diseases
Chinese Academy of Medical Sciences
and Peking Union Medical College
167 Beilishi Road
Beijing 100037
China
E-mail: tangyida@fuwaihospital.org
810 ZHANG ET AL.
